Darbepoetin alfa biosimilar - Dong-A ST

Drug Profile

Darbepoetin alfa biosimilar - Dong-A ST

Alternative Names: DA-3880; Darbepoetin α biosimilar - Dong-A Pharmaceutical; GBS-011

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST; Sanwa Kagaku Kenkyusho
  • Class Antianaemics; Erythropoietins; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Anaemia

Highest Development Phases

  • Phase I Anaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in Netherlands (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in Netherlands (SC, Injection)
  • 24 Jun 2016 Darbepoetin alfa biosimilar is available for licensing except in Japan as of 24 June 2016. http://www.donga-pharm.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top